Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0211 | 0.8972 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.023 | 1 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0197 | 0.8236 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0189 | 0.7809 | 0.8703 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Echinococcus multilocularis | methionine synthase reductase | 0.0117 | 0.3975 | 0.4431 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0094 | 0.276 | 0.5 |
Echinococcus granulosus | voltage gated potassium channel | 0.0061 | 0.1028 | 0.1145 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 0.8703 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0117 | 0.3975 | 0.4431 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0095 | 0.2836 | 0.2836 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 1 |
Giardia lamblia | Hypothetical protein | 0.0167 | 0.6669 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0189 | 0.7809 | 0.9481 |
Chlamydia trachomatis | sulfite reductase | 0.0117 | 0.3975 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0189 | 0.7809 | 0.8703 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0061 | 0.1028 | 0.1028 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 0.8703 |
Leishmania major | p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Treponema pallidum | flavodoxin | 0.0072 | 0.162 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0197 | 0.8236 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0117 | 0.3975 | 0.4431 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0189 | 0.7809 | 1 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0211 | 0.8972 | 1 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0061 | 0.1028 | 0.1145 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0189 | 0.7809 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0167 | 0.6669 | 0.8097 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0117 | 0.3975 | 0.3975 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0189 | 0.7809 | 1 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0061 | 0.1028 | 0.1145 |
Loa Loa (eye worm) | hypothetical protein | 0.0189 | 0.7809 | 0.8703 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0211 | 0.8972 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0094 | 0.276 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0189 | 0.7809 | 0.8703 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Brugia malayi | flavodoxin family protein | 0.0072 | 0.162 | 0.1806 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0072 | 0.162 | 0.1806 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0061 | 0.1028 | 0.1145 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0167 | 0.6669 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0167 | 0.6669 | 0.8159 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0189 | 0.7809 | 0.8703 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0094 | 0.276 | 0.276 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0061 | 0.1028 | 0.1028 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0189 | 0.7809 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0189 | 0.7809 | 0.8703 |
Loa Loa (eye worm) | hypothetical protein | 0.0061 | 0.1028 | 0.1145 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Echinococcus granulosus | methionine synthase reductase | 0.0117 | 0.3975 | 0.4431 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0211 | 0.8972 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0183 | 0.7495 | 0.8354 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0189 | 0.7809 | 0.7809 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0167 | 0.6669 | 0.8159 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0061 | 0.1028 | 0.1145 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 68.7 uM | Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method | ChEMBL. | 16879965 |
IC50 (functional) | = 68.7 uM | Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method | ChEMBL. | 16879965 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.